title: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
abstract: OBJECTIVE
  Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners.
  
  
  METHODS
  This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the field and are based on randomized controlled studies.
  
  
  RESULTS
  First-line pharmacological treatments for these disorders are selective serotonin reuptake inhibitors (for all disorders), serotonin-norepinephrine reuptake inhibitors (for some) and pregabalin (for generalized anxiety disorder only). A combination of medication and cognitive behavior/exposure therapy was shown to be a clinically desired treatment strategy.
  
  
  CONCLUSIONS
  This short version of an evidence-based guideline may improve treatment of anxiety disorders, OCD, and PTSD in primary care.
authors.affiliation: Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany. Borwin.Bandelow@medizin.uni-goettingen.de
authors.forename: Borwin
authors.initials: B
authors.lastname: Bandelow
authors.forename: Leo
authors.initials: L
authors.lastname: Sher
authors.forename: Robertas
authors.initials: R
authors.lastname: Bunevicius
authors.forename: Eric
authors.initials: E
authors.lastname: Hollander
authors.forename: Siegfried
authors.initials: S
authors.lastname: Kasper
authors.forename: Joseph
authors.initials: J
authors.lastname: Zohar
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D000069583:Pregabalin; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006633:Histamine Antagonists; D000069583:Pregabalin; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid